Limits...
Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study examined gastroenterologists’ motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.

Methods: Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken in 2015–2016 with German gastroenterologists and patients with ulcerative colitis or Crohn’s disease. Gastroenterologists provided data on their prescribing behaviour and attitudes towards biosimilars, and invited the next eight eligible consecutive consulting patients to complete a detailed questionnaire. For analysis, gastroenterologists were split into ‘Investigative’, ‘Conservative’, and ‘Other’ groups.

Results: Overall, 25 gastroenterologists and 136 patients participated. Biosimilars accounted for <15% of all biologic therapies and >80% of gastroenterologists would prescribe a bio-originator rather than biosimilar as 1st line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, although of those receiving biosimilars, 79% were satisfied with the current treatment of their condition, and 69% were satisfied with the control of symptoms. Although at least 35% of patients in each analysis group reported no concerns when starting treatment with a bio-originator or biosimilar, 41% of previously biologic-naïve patients prescribed a biosimilar indicated potential side effects and potential long-term problems, and 24% not knowing enough about the drug, as concerns.

Conclusion: Results demonstrate that there is reluctance from patients to accept biosimilars and the need to further educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into non-clinical switching and the long term impact of prescribing biosimilars.

No MeSH data available.


Related in: MedlinePlus

Gastroenterologist prescribing preference when it is assumed there are no restrictions or guidelines.“Blue”- Bio-originator, “red”—Biosimilar. CD, Crohn’s disease; UC, ulcerative colitis.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5391967&req=5

pone.0175826.g001: Gastroenterologist prescribing preference when it is assumed there are no restrictions or guidelines.“Blue”- Bio-originator, “red”—Biosimilar. CD, Crohn’s disease; UC, ulcerative colitis.

Mentions: Gastroenterologists reported that biosimilars made up 12–13% of the biologic therapies and 4–5% of all drugs that they prescribed for the two conditions under study (Table 1). There was little expectation that this would increase over the following 12 months (Table 1). When asked about their preferences for prescribing under the assumption of unrestricted circumstances (i.e. no prescribing guidelines or other restrictions), 88% of gastroenterologists indicated they would prefer to prescribe a bio-originator to a biosimilar as 1st line therapy for either UC or CD (Fig 1). This decreased to 72% and 80% for UC and CD, respectively for 2nd line. When considering 3rd line therapy, if no restrictions applied 92% of gastroenterologists would prefer to prescribe a bio-originator for UC, but only 76% for CD (Fig 1).


Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany
Gastroenterologist prescribing preference when it is assumed there are no restrictions or guidelines.“Blue”- Bio-originator, “red”—Biosimilar. CD, Crohn’s disease; UC, ulcerative colitis.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5391967&req=5

pone.0175826.g001: Gastroenterologist prescribing preference when it is assumed there are no restrictions or guidelines.“Blue”- Bio-originator, “red”—Biosimilar. CD, Crohn’s disease; UC, ulcerative colitis.
Mentions: Gastroenterologists reported that biosimilars made up 12–13% of the biologic therapies and 4–5% of all drugs that they prescribed for the two conditions under study (Table 1). There was little expectation that this would increase over the following 12 months (Table 1). When asked about their preferences for prescribing under the assumption of unrestricted circumstances (i.e. no prescribing guidelines or other restrictions), 88% of gastroenterologists indicated they would prefer to prescribe a bio-originator to a biosimilar as 1st line therapy for either UC or CD (Fig 1). This decreased to 72% and 80% for UC and CD, respectively for 2nd line. When considering 3rd line therapy, if no restrictions applied 92% of gastroenterologists would prefer to prescribe a bio-originator for UC, but only 76% for CD (Fig 1).

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study examined gastroenterologists’ motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.

Methods: Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken in 2015–2016 with German gastroenterologists and patients with ulcerative colitis or Crohn’s disease. Gastroenterologists provided data on their prescribing behaviour and attitudes towards biosimilars, and invited the next eight eligible consecutive consulting patients to complete a detailed questionnaire. For analysis, gastroenterologists were split into ‘Investigative’, ‘Conservative’, and ‘Other’ groups.

Results: Overall, 25 gastroenterologists and 136 patients participated. Biosimilars accounted for <15% of all biologic therapies and >80% of gastroenterologists would prescribe a bio-originator rather than biosimilar as 1st line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, although of those receiving biosimilars, 79% were satisfied with the current treatment of their condition, and 69% were satisfied with the control of symptoms. Although at least 35% of patients in each analysis group reported no concerns when starting treatment with a bio-originator or biosimilar, 41% of previously biologic-naïve patients prescribed a biosimilar indicated potential side effects and potential long-term problems, and 24% not knowing enough about the drug, as concerns.

Conclusion: Results demonstrate that there is reluctance from patients to accept biosimilars and the need to further educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into non-clinical switching and the long term impact of prescribing biosimilars.

No MeSH data available.


Related in: MedlinePlus